Presidio Pharmaceuticals, Inc. is a San Francisco-based clinical-stage pharmaceutical company dedicated to the development and licensing of its small-molecule antiviral therapeutic, ravidasvir (PPI-668) in the treatment of hepatitis C virus (HCV) infection. With a compound targeting the NS5A protein of HCV, Presidio is positioned to compete in the HCV therapy market (see Programs & Pipeline…